Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Osteopetrosis-associated transmembrane protein 1 (OSTM1)
- Target
- OSTM1
- Molecular classification
- Transmembrane protein, Accessory subunit of chloride channel (CLCN7 beta subunit), E3 ubiquitin ligase (contains RING finger-like domain)
01
Overview
Osteopetrosis-associated transmembrane protein 1 (OSTM1) is a highly conserved type I transmembrane protein essential for the maturation and function of both osteoclasts and melanocytes. OSTM1 acts as an accessory beta subunit for chloride channel 7 (CLCN7), playing a pivotal role in acidification of the osteoclast resorptive lacuna, thus regulating bone resorption. It also participates in the ubiquitin-dependent degradation of G proteins, possibly through its E3 ubiquitin ligase activity. Mutations or dysfunction of the OSTM1 gene result in severe autosomal recessive infantile malignant osteopetrosis, characterized by defective bone resorption, marrow failure, and accompanying neurological symptoms in some cases. OSTM1 is not currently a direct therapeutic target, and there are no drugs known to act on this protein, but it plays a central role in the biology of osteoclasts and is a critical disease gene for severe osteopetrosis.
- Other names
- Osteoclastogenesis associated transmembrane protein 1GLHSPC019GIPNOPTB5Chloride channel 7 beta subunitCLCN7 accessory beta subunitgrey-lethal
02
Biological functions
Osteoclast maturation and differentiationMelanocyte maturation and functionRegulation of protein degradation via the ubiquitin-proteasome pathwayInteraction with regulator of G-protein signaling (RGS) proteins
03
Disease associations
Osteopetrosis, particularly infantile malignant autosomal recessive osteopetrosis (Albers-Schonberg disease)Neurodegenerative disease (due to lysosomal storage impairment in some contexts)
04
Safety considerations
Deficiency or dysfunction causes severe bone disease (osteopetrosis)Potential broader effects due to its role in critical cell differentiation pathways
Beyond the preview
Go deeper on Osteopetrosis-associated transmembrane protein 1 (OSTM1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Osteopetrosis-associated transmembrane protein 1 (OSTM1).